Snapshot
Idex Corp /De/ reported $865M of revenue in Q2 2025, up 7.2% year over year, with diluted EPS of $1.74 and an operating margin of 21.7%.
- Revenue
- $865M
- YoY growth
- +7.2%
- Diluted EPS
- $1.74
- Operating margin
- 21.7%
What management said
- •We released our second quarter financial results earlier this morning, and you can find both our press release and earnings call slide presentation in the Investor Relations section of our website, idexcorp.com.
- •I'd like to walk through a real-time growth example of this dynamic tuning at Airtech, a business acquired in 2021 within HST, to illustrate our team's agility in action.
- •Four years ago, at the time of acquisition, their product lines were growing within mutually exclusive application sets supported by good operational performance with room for targeted improvements.
- •It demonstrates the power of our dynamic business model, our commitment to 80/20, and the leverage of IDEX's global capabilities with proprietary capital deployment via M&A as the key catalyst.
- •We're confident in the pneumatics team's plans to drive even more growth and value creation in the quarters and years to come.
- •Within Q2, there were some strong demand influence in the form of trade policy positioning statements that were unpredictable, shocking the system and setting up sine waves of up-and-down order patterns.
- •Daily demand levels moved dynamically between policy announcements and negotiation deadlines as customers attempted to de-risk tariff and pricing exposure.
- •Second, and most important for us, the sudden and unpredictable shifts in policy are slowing down decision-making and conviction for larger orders.
- •This has the highest go-forward impact for us in some more recently acquired areas of IDEX, where strong growth funnels supported earlier expectations of accelerating back half revenue and margins.
- •Coupling this with our long-established operational capabilities, we believe we are very well positioned to drive attractive growth and value for all of our stakeholders.
- •Our goal is simple: extend IDEX's growth potential through variable levels of integration to win in advantaged markets where customers are demanding more solutions impact than any one single business unit can provide alone.
- •First is HST's IDEX Health & Science platform that we built through thoughtful capital deployment over the last 20 years.
What went well
- •All three segments delivered better-than-expected Q2 results despite continued macro uncertainty, with the company outperforming on both adjusted EBITDA margin and adjusted EPS.
- •Organic orders grew 2% with positive demand in pharmaceutical, energy, and agriculture end markets and continued stability in diversified industrial and water.
- •HST organic sales grew 4%, supported by positive price and volume increases in pharmaceutical, space, defense, and data center-focused businesses.
- •FMT adjusted EBITDA margin rose 130 basis points year over year to 35% as positive price, cost, and productivity more than offset volume deleverage.
- •Free cash flow grew 25% year over year to $147 million, representing 94% conversion versus adjusted net income, helped by higher earnings and favorable receivables timing.
- •Platform optimization, delayering, and cost containment efforts delivered a combined $14 million in savings during the quarter, on track for $62 million in full-year savings.
What went wrong
- •Management lowered second-half financial projections, citing sudden and unpredictable trade-policy shifts that slowed decision-making and conviction on larger orders, especially in recently acquired HST businesses.
- •Softness persisted in automotive, rescue tool, and parts of the semiconductor businesses, with advanced semiconductor lithography demand facing headwinds.
- •A key semiconductor customer in the Muon/MSS business lowered growth expectations, leaving that high-margin lithography componentry flat for an extended period.
- •Adjusted EBITDA margin declined 40 basis points year over year to 27.4%, reflecting Mott acquisition dilution, unfavorable mix, volume deleverage, and lower variable compensation in the prior-year period.
- •Backlog reductions for IDEX came almost entirely out of the month of June as frozen customer decision-making delayed orders ahead of the July tariff deadlines.
Guidance changes
| Metric | Period | Previous | Current | Change |
|---|---|---|---|---|
| Full-year organic sales growth | FY2025 | 1-3% | approximately 1% | Lowered |
| Full-year adjusted EPS | FY2025 | $8.10-$8.45 | $7.85-$7.95 | Lowered |
| Organic revenue growth | Q3 2025 | — | 2-3% | New |
| Adjusted EPS | Q3 2025 | — | $1.90-$1.95 | New |
| Tariff impact | FY2025 | $100 million | approximately $50 million (about two-thirds recognized in 2025) | Lowered |
Performance breakdown
| Metric | YoY change | Reason |
|---|---|---|
| Total organic orders | +2% | Positive demand in pharmaceutical, energy, and agriculture end markets, plus stability in diversified industrial and water, partly offset by softness in automotive, rescue tool, and semiconductor. |
| Total organic sales | +1% | Positive price across all three segments and strength in aerospace, defense, data centers, pharmaceuticals, and North American fire OEMs, masked by tough prior-year comparisons and semiconductor and automotive weakness. |
| Adjusted gross margin | -10 bps | Near-term dilution from the Mott acquisition, unfavorable mix, and volume deleverage, partially offset by favorable price-cost and operational productivity. |
| Adjusted EBITDA margin | -40 bps (to 27.4%) | Gross margin performance plus lower variable compensation expense in the prior-year second quarter. |
| HST organic orders | +2% | Demand for advanced semiconductor lithography solutions and automotive continued to face headwinds. |
| HST organic sales | +4% | Positive price and volume increases within pharmaceutical, space, defense, and data center-focused businesses. |
| HST adjusted EBITDA margin | 26% (up 40 bps sequentially) | Tracked lower than anticipated given mix pressure within Material Science Solutions and Mott Corporation. |
| FMT organic orders | +7% | Growth in downstream energy, agriculture, and municipal water, though industrial distribution pulled back in June after in-line rates through May. |
| FMT organic sales | -2% | Chemical, energy, and agriculture declined against challenging prior-year comparables; semiconductor remained challenging and water was down on timing; positive price was a partial offset. |
| FMT adjusted EBITDA margin | +130 bps (to 35%) | Positive price, cost, and productivity improvements more than offset volume deleverage. |
| FST organic sales | +2% | Strong OEM demand and adoption of integrated fire and safety solutions. |
| FST organic orders | -7% | Choppy near-term order patterns attributed mostly to timing in both fire and safety and dispensing businesses. |
| FST adjusted EBITDA margin | +40 bps (to 29.4%) | Positive price-cost more than offset net productivity, volume deleverage, and mix headwinds. |
| Price capture | just under 3% | Roughly 1% base price implemented in Q1 plus an added tariff-response pricing layer in Q2. |
Earnings call themes & trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| Trade policy / tariff-driven order volatility | — | Unpredictable policy statements created sine-wave order patterns and froze larger-order decision-making, with recovery building through July; roughly 90% of customer conversations are trade-policy related. | rising |
| Mott (MOT) integration and ramp | High-single-digit growth expected when announced | Now expected to be roughly flat for the year given the order pause, but still positioned for a strong Q4 and double-digit returns over the longer horizon; confirmed accretive. | declining |
| Semiconductor mix (Muon/MSS lithography) | Inventory correction with expected acceleration | Key customer settled into steady demand amid geopolitical restrictions, leaving high-margin lithography business flat and pressuring mix. | declining |
| Bolt-on / tuck-in M&A and platform building | More aggressive acquisitions over the last four years | Announced MicroLam tuck-in for the MSS/Optical Technologies platform; funnel froze early in the quarter but activity is picking back up, with tuck-ins required to touch an existing IDEX business. | steady |
| Data center exposure | — | Growing portion of the Airtech pneumatics business (fuel cell power support, liquid cooling thermal management) plus emerging niche wins in the Muon Group; not yet a major IDEX catalyst. | rising |
| Cost actions and productivity | Three buckets totaling savings plans | $42M platform optimization/delayering at run rate (about $20M year to date) and $20M cost containment ramping to run rate this quarter; baseline productivity remains volume-dependent. | steady |
Q&A summary
What is your confidence that delayed larger orders, including semi, will actually come through in the back half rather than be deferred indefinitely?
Order recovery built through July on both small orders and larger decision-making, and customers now see a more predictable settling point, giving better confidence; however, the high-margin Muon lithography piece looks set to stay flatter for a while due to geopolitical restrictions.
Does the back-half margin cut reflect outsized impact from very high-margin businesses not getting volume, and should margins recover when those orders come in?
Yes, largely on the HST side - a return to growth in the best acquired business will help profitability, alongside tuning and revenue acceleration at MOT for full leverage.
How much of the guidance cut is attributable specifically to MOT?
Two main areas - the MSS group's flattened high-margin semi-lithography mix, and MOT's non-linear ramp where frozen Q2 decision-making created a Q4 production physics constraint; a trailing third came from small-order patterns delaying cross-IDEX Q3 momentum.
Can you size your data center exposure and where it can go over the next few years?
It is not a giant part of IDEX - a growing portion of the Airtech business plus a peripheral win in the Muon Group; these are early niche wins management intends to scale and dimensionalize over time.
Can you explain the strategic fit of the MicroLam acquisition with the MSS platform?
MicroLam makes precision optics that complement IDEX's coating, polishing, and assembly capabilities, with strong space and defense customer touchpoints; it sits in the MSS platform and is expected to be accretive in the first full year of ownership.
Level set us on the cost and productivity actions accomplished and remaining, and the volume risk to them.
The $42M platform optimization/delayering is at run rate with about $20M achieved year to date; the $20M cost containment hits run rate this quarter (about $23M combined so far), with the balance in the back half; baseline productivity remains dependent on volume ramping in Q3 and Q4.